{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T18:20:11Z","timestamp":1789237211232,"version":"build-2803163510"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"50","license":[{"start":{"date-parts":[[2020,12,11]],"date-time":"2020-12-11T00:00:00Z","timestamp":1607644800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Zhejiang Medical and Health Science and Technology Program","award":["2016DTA001"],"award-info":[{"award-number":["2016DTA001"]}]},{"DOI":"10.13039\/501100005199","name":"Chinese Medicine Research Program of Zhejiang Province","doi-asserted-by":"crossref","award":["2020ZA018"],"award-info":[{"award-number":["2020ZA018"]}],"id":[{"id":"10.13039\/501100005199","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Peripheral neurotoxicity (PN) is a frequent side effect of oxaliplatin treatment, and also is its dose-limiting toxicity. Studies have confirmed that \u03c9-3 polyunsaturated fatty acids (\u03c9-3 PUFAs) had a neuroprotective effect. However, the efficacy of \u03c9-3 PUFAs on the prevention of oxaliplatin-related neurotoxicity remains unclear. We assessed the effect of \u03c9-3 PUFAs on the neurotoxicity in colon cancer patients treated by oxaliplatin combined with capecitabine.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>In a randomized, double-blind, placebo-controlled study, 179 patients with colon cancer receiving oxaliplatin combined with capecitabine were recruited, and randomly assigned to take \u03c9-3 PUFAs, 640\u200amg t.i.d during chemotherapy and 1 month after the end of the treatment or placebo. All patients were treated with chemotherapy for 6 treatment cycles. The incidence and severity of PN were evaluated, and the nerve conduction was measured before the onset of chemotherapy and 1 month after treatment. In addition, the quality of life was also accessed using Chinese version of European organization for research and treatment of cancer quality of life questionnaire.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The incidence of PN in the \u03c9-3 PUFAs group and placebo group was 52.22% and 69.66%, respectively (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.017). In addition, there was a significant difference in the severity of PN between the 2 groups (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.017). In terms of motor and sensory nerve conduction, the sensory action potentials amplitude of sural nerve in the \u03c9-3 PUFAs group and placebo group after chemotherapy treatment were (15.01\u200a\u00b1\u200a3.14) and (13.00\u200a\u00b1\u200a3.63) \u03bc V respectively, suggesting there was a significant difference in the 2 groups (<jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.000). In addition, the mean score of the global health-status\/quality of life was obviously higher in the \u03c9-3 PUFAs group than that in the placebo group.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>\u03c9-3 PUFAs seem to reduce the incidence and severity of oxaliplatin-related neurotoxicity, and improve the quality of patients\u2019 life, indicating it is expected to be a potential drug for the treatment of oxaliplatin-related neurotoxicity.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000023564","type":"journal-article","created":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T22:06:06Z","timestamp":1607637966000},"page":"e23564","source":"Crossref","is-referenced-by-count":16,"title":["Prevention of oxaliplatin-related neurotoxicity by \u03c9-3 PUFAs"],"prefix":"10.1097","volume":"99","author":[{"given":"Xinjie","family":"Zhang","sequence":"first","affiliation":[{"name":"Zhejiang Chinese Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Chen","sequence":"additional","affiliation":[{"name":"Zhejiang Chinese Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Nutrition"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Integrated Traditional Chinese and Western Medicine, the Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Yao","sequence":"additional","affiliation":[{"name":"Zhejiang Chinese Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Xu","sequence":"additional","affiliation":[{"name":"Zhejiang Chinese Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runzhe","family":"Zhang","sequence":"additional","affiliation":[{"name":"Zhejiang Chinese Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Zhang","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Zhejiang Chinese Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinghua","family":"Yao","sequence":"additional","affiliation":[{"name":"Department of Integrated Traditional Chinese and Western Medicine, the Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)"},{"name":"Key Laboratory of Traditional Chinese Medicine Oncology, the Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,12,11]]},"reference":[{"key":"R1-20230916","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"R2-20230916","doi-asserted-by":"crossref","first-page":"359","DOI":"10.6004\/jnccn.2018.0021","article-title":"NCCN guidelines insights: colon cancer, version 2.2018","volume":"16","author":"Benson","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"R3-20230916","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s00280-009-0938-4","article-title":"Oxaliplatin, irinotecan, and fluorouracil\/folinic acid in advanced gastric cancer: a multicenter phase II trial of the southern Italy cooperative oncology group","volume":"64","author":"Comella","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"R4-20230916","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.jpainsymman.2017.07.033","article-title":"Oxaliplatin-induced peripheral neuropathy and identification of unique severity groups in colorectal cancer","volume":"54","author":"Griffith","year":"2017","journal-title":"J Pain Symptom Manage"},{"key":"R5-20230916","doi-asserted-by":"crossref","first-page":"4781","DOI":"10.1007\/s00520-020-05319-x","article-title":"Predictive clinical factors of chronic peripheral neuropathy induced by oxaliplatin","volume":"28","author":"Yildirim","year":"2020","journal-title":"Support Care Cancer"},{"key":"R6-20230916","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1007\/s00520-014-2242-z","article-title":"A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration","volume":"22","author":"Beijers","year":"2014","journal-title":"Support Care Cancer"},{"key":"R7-20230916","doi-asserted-by":"crossref","first-page":"e18469","DOI":"10.1371\/journal.pone.0018469","article-title":"Dose effects of oxaliplatin on persistent and transient Na+ conductances and the development of neurotoxicity","volume":"6","author":"Park","year":"2011","journal-title":"PLoS One"},{"key":"R8-20230916","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1158\/1078-0432.CCR-03-0666","article-title":"Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer","volume":"10","author":"Gamelin","year":"2004","journal-title":"Clin Cancer Res"},{"key":"R9-20230916","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.ejca.2010.10.006","article-title":"The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients","volume":"47","author":"Knijn","year":"2011","journal-title":"Eur J Cancer"},{"key":"R10-20230916","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.plefa.2017.07.003","article-title":"DHA, EPA and their combination at various ratios differently modulated Abeta25-35-induced neurotoxicity in SH-SY5Y cells","volume":"136","author":"Zhang","year":"2018","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"key":"R11-20230916","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s13105-015-0395-y","article-title":"An update on the role of omega-3 fatty acids on inflammatory and degenerative diseases","volume":"71","author":"Lorente-Cebrian","year":"2015","journal-title":"J Physiol Biochem"},{"key":"R12-20230916","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1177\/1534735418803758","article-title":"Prevention of bortezomib-related peripheral neuropathy with docosahexaenoic acid and alpha-lipoic acid in patients with multiple myeloma: preliminary data","volume":"17","author":"Maschio","year":"2018","journal-title":"Integr Cancer Ther"},{"key":"R13-20230916","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1186\/1471-2407-12-355","article-title":"Omega-3 fatty acids are protective against paclitaxel-induced peripheral neuropathy: a randomized double-blind placebo controlled trial","volume":"12","author":"Ghoreishi","year":"2012","journal-title":"BMC Cancer"},{"key":"R14-20230916","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1053\/sonc.2002.35525","article-title":"Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures","volume":"29","author":"Gamelin","year":"2002","journal-title":"Semin Oncol"},{"key":"R15-20230916","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1515\/raon-2017-0021","article-title":"Health-related quality of life assessed by the EORTC QLQ-C30 questionnaire in the general Slovenian population","volume":"51","author":"Velenik","year":"2017","journal-title":"Radiol Oncol"},{"key":"R16-20230916","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.clcc.2017.03.013","article-title":"Neurotoxicity outcomes in a population-based cohort of elderly patients treated with adjuvant oxaliplatin for colorectal cancer","volume":"16","author":"Raphael","year":"2017","journal-title":"Clin Colorectal Cancer"},{"key":"R17-20230916","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/cncr.27732","article-title":"Clinical pattern and associations of oxaliplatin acute neurotoxicity: a prospective study in 170 patients with colorectal cancer","volume":"119","author":"Argyriou","year":"2013","journal-title":"Cancer"},{"key":"R18-20230916","first-page":"294","article-title":"Peripheral neuropathy: pathogenic mechanisms and alternative therapies","volume":"11","author":"Head","year":"2006","journal-title":"Altern Med Rev"},{"key":"R19-20230916","doi-asserted-by":"crossref","first-page":"723","DOI":"10.3389\/fphar.2017.00723","article-title":"Long-chain omega-3 fatty acids supplementation accelerates nerve regeneration and prevents neuropathic pain behavior in mice","volume":"8","author":"Silva","year":"2017","journal-title":"Front Pharmacol"},{"key":"R20-20230916","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jnutbio.2015.11.009","article-title":"Docosahexaenoic acid confers analgesic effects after median nerve injury via inhibition of C-Jun N-terminal kinase activation in microglia","volume":"29","author":"Huang","year":"2016","journal-title":"J Nutr Biochem"},{"key":"R21-20230916","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/j.bbamem.2017.05.003","article-title":"The role of omega-3 and omega-9 fatty acids for the treatment of neuropathic pain after neurotrauma","volume":"1859","author":"Galan-Arriero","year":"2017","journal-title":"Biochim Biophys Acta Biomembr"},{"key":"R22-20230916","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1179\/1476830513Y.0000000074","article-title":"Fish oil protects the peripheral and central nervous systems against cisplatin-induced neurotoxicity","volume":"17","author":"Kamisli","year":"2013","journal-title":"Nutr Neurosci"},{"key":"R23-20230916","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00520-005-0776-9","article-title":"Peripheral neuropathy induced by administration of cisplatin- and paclitaxel-based chemotherapy. Could it be predicted?","volume":"13","author":"Argyriou","year":"2005","journal-title":"Support Care Cancer"},{"key":"R24-20230916","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1097\/IGC.0000000000001320","article-title":"The influence of chemotherapy-induced peripheral neuropathy on quality of life of gynecologic cancer survivors","volume":"28","author":"Matsuoka","year":"2018","journal-title":"Int J Gynecol Cancer"},{"key":"R25-20230916","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1186\/s13063-018-2874-2","article-title":"The evaluation of changes in peripheral neuropathy and quality-of-life using low-frequency electrostimulation in patients treated with chemotherapy for breast cancer: a study protocol","volume":"19","author":"Jang","year":"2018","journal-title":"Trials"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000023564","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T04:16:11Z","timestamp":1694837771000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000023564"}},"subtitle":["A double-blind randomized study of patients receiving oxaliplatin combined with capecitabine for colon cancer"],"short-title":[],"issued":{"date-parts":[[2020,12,11]]},"references-count":25,"journal-issue":{"issue":"50","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000023564","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,11]]}}}